Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01200004 · ClinicalTrials.gov registry record · Phase 1
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01200004: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01200004 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01200004, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of Grifola frondosa extract, azacitidine, and lenalidomide that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
Primary Outcome
MTD defined by patient dose limiting toxicities (DLTs) that occur in the first cycle (4 weeks).
Interventions
- DRUG Azacitidine
- DRUG Lenalidomide
- DRUG Grifola Frondosa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Why NCT01200004 stopped before completion
NCT01200004 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Azacitidine is the first listed.
NCT01200004 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01200004 about?
NCT01200004 is a clinical study titled "Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide". The goal of this clinical research study is to find the highest tolerable dose of the combination of Grifola frondosa extract, azacitidine, and lenalidomide that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
What is the current status of trial NCT01200004?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2012-04. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01200004?
The interventions under investigation include: Azacitidine (DRUG), Lenalidomide (DRUG), Grifola Frondosa (DRUG).
Who is sponsoring clinical trial NCT01200004?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01200004's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia